Glycopolymer and Poly(β-amino ester)-Based Amphiphilic Block Copolymer as a Drug Carrier.

in Biomacromolecules by Elif L Sahkulubey Kahveci, Muhammet U Kahveci, Asuman Celebi, Timucin Avsar, Serap Derman

TLDR

  • The study made a special kind of medicine called P(MAG--HEMA)--PBAE that can target cancer cells. The medicine has a special sugar on it that cancer cells like to stick to. The medicine also changes how it works depending on how acidic or basic it is. The study showed that the medicine only works on cancer cells and not on healthy cells. The study also showed that the medicine can release its medicine in a special way depending on how acidic or basic it is. The study suggests that this medicine could be used to treat cancer.

Abstract

Glycopolymers are synthetic macromolecules having pendant sugar moieties and widely utilized to target cancer cells. They are usually considered as a hydrophilic segment of amphiphilic block copolymers to fabricate micelles as drug carriers. A novel amphiphilic block copolymer, namely, poly(2-deoxy-2-methacrylamido-d-glucose--2-hydroxyethyl methacrylate)--poly(β-amino ester) [P(MAG--HEMA)--PBAE], with active cancer cell targeting potential and pH responsivity was prepared. Tetrazine end functional P(MAG--HEMA) and norbornene end functional PBAE blocks were separately synthesized through reversible addition fragmentation chain transfer polymerization and Michael addition-based poly-condensation, respectively, and followed by end-group transformation. Then, inverse electron demand Diels Alder reaction between the tetrazine and the norbornene groups was performed by simply mixing to obtain the amphiphilic block copolymer. After characterization of the block copolymer in terms of chemical structure, pH responsivity, and drug loading/releasing, pH-responsive micelles were obtained with or without doxorubicin (DOX), a model anticancer drug. The micelles exhibited a sharp protonated/deprotonated transition on tertiary amine groups around pH 6.75 and the pH-specific release of DOX below this value. Eventually, the drug delivery potential was evaluated by cytotoxicity assays on both the noncancerous human umbilical vein endothelial cell (HUVEC) cell line and glioblastoma cell line, U87-MG. While the DOX-loaded polymeric micelles were not toxic in noncancerous HUVEC cells, being toxic only to the cancer cells indicates that it is a potential specific cell targeting strategy in the treatment of cancer.

Overview

  • The study focuses on the synthesis and characterization of a novel amphiphilic block copolymer, P(MAG--HEMA)--PBAE, with active cancer cell targeting potential and pH responsivity. The copolymer was prepared through reversible addition fragmentation chain transfer polymerization and Michael addition-based poly-condensation, followed by inverse electron demand Diels Alder reaction between the tetrazine and norbornene groups. The study aims to investigate the pH-responsive drug delivery potential of the copolymer and its ability to target cancer cells. The primary objective is to evaluate the cytotoxicity of the DOX-loaded polymeric micelles on both noncancerous and cancerous cells.

Comparative Analysis & Findings

  • The study compared the pH-responsive drug delivery potential of the P(MAG--HEMA)--PBAE copolymer with and without DOX loading. The results showed that the DOX-loaded micelles were toxic only to cancer cells, indicating specific cell targeting potential. The study also demonstrated the pH-specific release of DOX below pH 6.75, which is a potential advantage in cancer treatment. The findings suggest that the P(MAG--HEMA)--PBAE copolymer could be a promising drug delivery system for cancer treatment.

Implications and Future Directions

  • The study's findings highlight the potential of the P(MAG--HEMA)--PBAE copolymer as a drug delivery system for cancer treatment. The specific cell targeting potential and pH-responsive drug release make it a promising candidate for further research. Future studies could focus on optimizing the copolymer's structure and properties for improved drug delivery and targeting specific cancer subtypes. Additionally, the study's findings could be applied to other drug delivery systems and cancer treatments.